Jerome Keith R
1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center , Seattle, Washington.
2 Virology Division, Department of Laboratory Medicine, University of Washington , Seattle, Washington.
AIDS Patient Care STDS. 2016 Dec;30(12):551-555. doi: 10.1089/apc.2016.0232. Epub 2016 Nov 17.
An effective approach to HIV cure will almost certainly require a combination of strategies, including some means of reducing the latent HIV reservoir. Because the integrated HIV provirus represents the major source of viral persistence and reactivation, one attractive approach is the direct targeting of provirus for disruption or excision using targeted endonucleases, such as CRISPR/Cas9, zinc finger nucleases, TAL effector nucleases, or meganucleases (homing endonucleases). This article highlights some of the challenges for successful endonuclease therapy for HIV, including optimization of enzyme activity and specificity, the possible emergence of viral resistance, and most importantly, efficient in vivo delivery of the enzymes to a sufficient portion of the latent reservoir.
一种有效的治愈艾滋病病毒的方法几乎肯定需要多种策略的结合,包括一些减少艾滋病病毒潜伏库的手段。由于整合的艾滋病病毒前病毒是病毒持续存在和重新激活的主要来源,一种有吸引力的方法是使用靶向核酸酶(如CRISPR/Cas9、锌指核酸酶、转录激活因子样效应物核酸酶或巨型核酸酶(归巢内切酶))直接靶向前病毒以进行破坏或切除。本文重点介绍了艾滋病病毒核酸酶治疗成功面临的一些挑战,包括酶活性和特异性的优化、病毒耐药性的可能出现,以及最重要的是,将酶有效地在体内递送至潜伏库的足够部分。